FLAMEL TECHNOLOGIES NAMES DR. PHILIPPE VIVET
VICE PRESIDENT AND DIRECTOR OF MEDICAL AFFAIRS

LYON, FRANCE, March 27, 1997 director at Sanofi Recherche, in France, where he was responsible for clinical development of internal medicine products in Europe. Previously, from 1989-1994, he was director of cardiovascular drug development at the Institut de Recherches International Servier, in Paris. Prior to that, he served as international coordinator of development of broncho-respiratory compounds at Roussel Uclaf in France. Dr. Vivet received his medical training at the Necker Medical School, Paris University.

Flamel currently has two products in advanced clinical development. ASACARD, the company's controlled-release aspirin designed to maintain aspirin's cardiovascular benefits with reduced gastric side effects, is the subject of applications for marketing approval filed in France and the U.K. VIROPUMP, a controlled-release formulation of aciclovir, designed to reduce the dosing frequency for the treatment of acute genital herpes from five times daily to twice daily, is now in a Phase III trial in Europe. The company is proceeding with other formulations based on its Micropump technology as well as with applications of its Medusa technology for the nanoencapsulation and protection against degradation of proteins and peptide-based drugs and vaccines.

"Dr. Vivet's extensive experience in the clinical development of significant pharmaceutical products will be most valuable to Flamel as we continue to advance our drug development programs," said Dr. Gérard Soula, Chief Executive Officer of Flamel Technologies.

Flamel Technologies is engaged in the development of advanced polymer technologies for unique drug delivery and biomaterial applications. The Company is building on its principal technology platforms -- through programs including Micropump and Medusa in drug-delivery, ColCys in biomaterial-based medical devices, and new materials for ophthalmic lens products -- to meet important unmet medical needs and develop other commercially valuable products. In June 1996, Flamel completed its initial public offering in the U.S.

NOTE : This press release contains statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties, including but not limited to the risk that this transaction will not be consummated, the risk associated with the Company's limited history of operations and historic and future losses, and the risk that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development , the impact of competitive products and pricing, reliance on outside parties and the risks associated with key strategic alliances, and other risks detailed in the Company's filings with the Securities and Exchange Commission.